Business Insights
  • Home
  • Crypto
  • Finance Expert
  • Business
  • Invest News
  • Investing
  • Trading
  • Forex
  • Videos
  • Economy
  • Tech
  • Contact

Archives

  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • August 2023
  • January 2023
  • December 2021
  • July 2021
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Categories

  • Business
  • Crypto
  • Economy
  • Finance Expert
  • Forex
  • Invest News
  • Investing
  • Tech
  • Trading
  • Uncategorized
  • Videos
Apply Loan
Money Visa
Advertise Us
Money Visa
  • Home
  • Crypto
  • Finance Expert
  • Business
  • Invest News
  • Investing
  • Trading
  • Forex
  • Videos
  • Economy
  • Tech
  • Contact
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
  • Business

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia

  • July 22, 2025
  • Roubens Andy King
Total
0
Shares
0
0
0
Total
0
Shares
Share 0
Tweet 0
Pin it 0

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, Rallybio Corporation (NASDAQ:RLYB) announced a definitive agreement to sell its interest in REV102 to its joint venture partner, Recursion Pharmaceuticals. The deal is valued at up to $25 million, with an upfront equity payment of $7.5 million and near-term milestone payments.

REV102 is an ENPP1 inhibitor currently in preclinical development for the treatment of hypophosphatasia/HPP, which is a rare inherited disorder affecting bone and tooth mineralization. The program originated from a joint venture between Rallybio and Recursion focused on discovering and developing novel, orally available small-molecule inhibitors of ENPP1 for HPP patients.

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia

A close-up of white lab coats and protective masks in a biotechnology research laboratory.

REV102, the lead candidate from this collaboration, entered IND-enabling studies in early 2025. Rallybio will also receive low single-digit royalties on all future net sales of REV102 by Recursion. Rallybio may also receive additional payments if Recursion sells the REV102 program to a third party.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that decodes biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the US.

Rallybio Corporation (NASDAQ:RLYB) is a clinical-stage biotechnology company that develops and commercializes life-transforming therapies for patients suffering from severe and rare diseases.

While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Roubens Andy King

Previous Article
Rick Rule’s Top 3 ASX Mining Stock Picks for Investors
  • Invest News

Rick Rule’s Top 3 ASX Mining Stock Picks for Investors

  • July 22, 2025
  • Roubens Andy King
Read More
Next Article
Vuzix, Ramblr Partner to Bring Advanced AI-Driven Intelligence to Enterprise Smart Glasses
  • Finance Expert

Vuzix, Ramblr Partner to Bring Advanced AI-Driven Intelligence to Enterprise Smart Glasses

  • July 22, 2025
  • Roubens Andy King
Read More
You May Also Like
Walmart+ adds Peacock to streaming offerings to better compete with Amazon Prime
Read More
  • Business

Walmart+ adds Peacock to streaming offerings to better compete with Amazon Prime

  • Roubens Andy King
  • September 3, 2025
Weak pound and yen shore up dollar, bonds and payrolls in focus
Read More
  • Business

Weak pound and yen shore up dollar, bonds and payrolls in focus

  • Roubens Andy King
  • September 3, 2025
Salesforce CEO Marc Benioff says he cut 4,000 support roles because of AI
Read More
  • Business

Salesforce CEO Marc Benioff says he cut 4,000 support roles because of AI

  • Roubens Andy King
  • September 2, 2025
Let’s Break Down What You Need to Be Watching This Week
Read More
  • Business

Let’s Break Down What You Need to Be Watching This Week

  • Roubens Andy King
  • September 2, 2025
Google won’t be forced to sell its Chrome browser, judge rules
Read More
  • Business

Google won’t be forced to sell its Chrome browser, judge rules

  • Roubens Andy King
  • September 2, 2025
Gold price hits record high as investors seek safe haven | Gold
Read More
  • Business

Gold price hits record high as investors seek safe haven | Gold

  • Roubens Andy King
  • September 2, 2025
How Is Chevron’s Stock Performance Compared to Other Oil & Gas Exploration & Production Stocks?
Read More
  • Business

How Is Chevron’s Stock Performance Compared to Other Oil & Gas Exploration & Production Stocks?

  • Roubens Andy King
  • September 2, 2025
Bunker Hill tower One California Plaza goes into receivership
Read More
  • Business

Bunker Hill tower One California Plaza goes into receivership

  • Roubens Andy King
  • September 2, 2025

Recent Posts

  • Shell (SHEL) Exceeds Market Returns: Some Facts to Consider
  • Ethereum Network Activity Heats Up As Fees Hit $1.4M In 24H
  • Ethereum Supply Shock? BitMine Absorbs 319,000 ETH In A Week
  • Oneok Inc. (OKE) Exceeds Market Returns: Some Facts to Consider
  • SEC delays decisions on several ETFs tied to staking and altcoins
Featured Posts
  • Shell (SHEL) Exceeds Market Returns: Some Facts to Consider 1
    Shell (SHEL) Exceeds Market Returns: Some Facts to Consider
    • September 10, 2025
  • Ethereum Network Activity Heats Up As Fees Hit .4M In 24H 2
    Ethereum Network Activity Heats Up As Fees Hit $1.4M In 24H
    • September 10, 2025
  • Ethereum Supply Shock? BitMine Absorbs 319,000 ETH In A Week 3
    Ethereum Supply Shock? BitMine Absorbs 319,000 ETH In A Week
    • September 10, 2025
  • Oneok Inc. (OKE) Exceeds Market Returns: Some Facts to Consider 4
    Oneok Inc. (OKE) Exceeds Market Returns: Some Facts to Consider
    • September 10, 2025
  • SEC delays decisions on several ETFs tied to staking and altcoins 5
    SEC delays decisions on several ETFs tied to staking and altcoins
    • September 10, 2025
Recent Posts
  • Is Paper Bitcoin Behind The Stagnant Bitcoin Price?
    Is Paper Bitcoin Behind The Stagnant Bitcoin Price?
    • September 10, 2025
  • Dow, S&P 500, Nasdaq futures nudge higher as Wall Street braces for key inflation data
    Dow, S&P 500, Nasdaq futures nudge higher as Wall Street braces for key inflation data
    • September 10, 2025
  • Ethereum Foundation Internal Update | Ethereum Foundation Blog
    Ethereum Foundation Internal Update | Ethereum Foundation Blog
    • September 10, 2025
Categories
  • Business (2,057)
  • Crypto (1,633)
  • Economy (123)
  • Finance Expert (1,687)
  • Forex (1,632)
  • Invest News (2,361)
  • Investing (1,554)
  • Tech (2,056)
  • Trading (2,024)
  • Uncategorized (2)
  • Videos (815)

Subscribe

Subscribe now to our newsletter

Money Visa
  • Privacy Policy
  • DMCA
  • Terms of Use
Money & Invest Advices

Input your search keywords and press Enter.